课题基金 / 基金详情

IL 2R SIGNALING PATHWAYS IN T CELL LYMPHOMA

IL 2R SIGNALING PATHWAYS IN T CELL LYMPHOMA
T 细胞淋巴瘤中的 IL 2R 信号通路
批准号:
6030064
负责人:
MARIUSZ A. WASIK
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-03-01 至 2001-02-28

项目摘要

项目成果

MARIUSZ A. WASIK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (adapted from the investigator's abstract) The purpose of this study is to investigate the role of cytokine mediated signal transduction pathway in the pathogenesis of human lymphomas. Specifically, the study will focus on the role of signals mediated through receptor for interleukin-2 (IL-2R) in the malignant transformation of T lymphocytes. Part of the IL-2R, common gamma chain (gamma c) is shared by receptors for several cytokines: IL-2, IL-4, IL-7, IL-9, and IL-15. Expression of the gamma c chain is essential for development and proliferation of normal T lymphocytes. In this study they will explore the expression, function and molecular structure of the gamma c and the cytokine-specific receptors which associate with gamma c by various types of malignant T-cell lymphoma. They will also examine whether the cytokines which signal through the cytokine receptors containing gamma c are synthesized and utilized by the malignant cells. Furthermore, they will study the expression, functional status, and structure of the IL-2R associated Jak/STAT signal transduction pathway as well as various, novel inhibitors of this pathway (members of the cytokine-receptor binding phosphatase, CIS/SOCS/SSI, and PIAS protein families). Finally, the expression, function, and structure of other molecles activated by IL-2R such as P13K, AKT, and STAM will also be determined. Particular attention will be paid to the possible differences in the IL-2R signaling between the indolent (low-grade/low stage) and aggressive (intermediate/high- grading/high state) variants of T-cell lymphoma. This study may result in a better understanding of the pathogenesis of at least some types of T-cell lymphoma. Consequently, it may lead to novel therapies for lymphoma based on selective inhibition of these elements of IL-2R signal transduction pathway(s) which are utilized by malignant T-cells.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/s0002-9440(10)64629-9
发表时间: 2000-10
期刊: The American journal of pathology
影响因子: --
作者: [Q. Zhang;P. N. Raghunath;E. Vonderheid;N. Odum;M. Wasik]
通讯作者: Q. Zhang;P. N. Raghunath;E. Vonderheid;N. Odum;M. Wasik
(m) TOR signaling in EBV-associated lymphomas
  • 批准号:
    7093171
  • 项目类别:
  • 资助金额:
    $27.09万
  • 财政年份:
    2005
  • 负责人:
    MARIUSZ A. WASIK
  • 依托单位:
(m) TOR signaling in EBV-associated lymphomas
  • 批准号:
    7231674
  • 项目类别:
  • 资助金额:
    $26.3万
  • 财政年份:
    2005
  • 负责人:
    MARIUSZ A. WASIK
  • 依托单位:
(m) TOR signaling in EBV-associated lymphomas
  • 批准号:
    7075814
  • 项目类别:
  • 资助金额:
    $27.74万
  • 财政年份:
    2005
  • 负责人:
    MARIUSZ A. WASIK
  • 依托单位:
Dysregulation of STAT3 in ALK-induced oncogenesis
  • 批准号:
    7086206
  • 项目类别:
  • 资助金额:
    $29.41万
  • 财政年份:
    2002
  • 负责人:
    MARIUSZ A. WASIK
  • 依托单位:
海外基金